Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 M IN DEXTROSE 10 IN PLASTIC CONTAINER versus HEPATASOL 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 M IN DEXTROSE 10 IN PLASTIC CONTAINER versus HEPATASOL 8.
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER vs HEPATASOL 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% M in Dextrose 10% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The amino acids undergo transamination, deamination, and incorporation into body proteins. Dextrose is metabolized via glycolysis, the Krebs cycle, and oxidative phosphorylation to produce ATP.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Intravenous infusion via central line. Adult dose: 500-2000 mL/day (equivalent to 21.25-85 g amino acids and 50-200 g dextrose) based on caloric and nitrogen requirements. Rate not to exceed 100 mL/hour initially, adjusted to maintain blood glucose <200 mg/dL.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
None Documented
None Documented
Amino acids: variable; individual amino acid half-lives range from minutes to hours; dextrose: 1-2 hours; clinical context: continuous infusion required to maintain stable plasma levels.
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
Renal: amino acids are metabolized and nitrogen is excreted primarily as urea (80-90%) and ammonia (minor); dextrose is fully metabolized to CO2 and water; negligible biliary/fecal elimination.
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution